Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges.

Autor: Hussen BM; Department of Biomedical Sciences, Cihan University-Erbil, Erbil, Kurdistan Region, 44001, Iraq.; Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Kurdistan Region, 44001, Iraq., Rasul MF; Department of Pharmaceutical Basic Science, Faculty of Pharmacy, Tishk International University, Erbil, Kurdistan Region, 44001, Iraq., Abdullah SR; Medical Laboratory Science, Lebanese French University, Erbil, Kurdistan Region, 44001, Iraq., Hidayat HJ; Department of Biology, College of Education, Salahaddin University-Erbil, Erbil, Kurdistan Region, 44001, Iraq., Faraj GSH; Department of Medical Laboratory Science, Komar University of Science and Technology, Sulaymaniyah, 46001, Iraq., Ali FA; Department of Medical Microbiology, College of Health Sciences, Hawler Medical University, Erbil, Kurdistan Region, 44001, Iraq., Salihi A; Department of Biology, College of Science, Salahaddin University-Erbil, Erbil, Kurdistan Region, 44001, Iraq.; Center of Research and Strategic Studies, Lebanese French University, Erbil, 44001, Iraq., Baniahmad A; Institute of Human Genetics, Jena University Hospital, 07747, Jena, Germany., Ghafouri-Fard S; Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, 374-37515, Iran., Rahman M; Department of Clinical Sciences, Malmö, Section for Surgery, Lund University, 22100, Malmö, Sweden., Glassy MC; Translational Neuro-Oncology Laboratory, San Diego (UCSD) Moores Cancer Center, University of California, San Diego, CA, 94720, USA., Branicki W; Faculty of Biology, Institute of Zoology and Biomedical Research, Jagiellonian University, 31-007, Kraków, Poland. wojciech.branicki@uj.edu.pl., Taheri M; Institute of Human Genetics, Jena University Hospital, 07747, Jena, Germany. mohammad.taheri@uni-jena.de.; Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, 374-37515, Iran. mohammad.taheri@uni-jena.de.
Jazyk: angličtina
Zdroj: Military Medical Research [Mil Med Res] 2023 Jul 17; Vol. 10 (1), pp. 32. Date of Electronic Publication: 2023 Jul 17.
DOI: 10.1186/s40779-023-00468-6
Abstrakt: Clustered regulatory interspaced short palindromic repeats (CRISPR) has changed biomedical research and provided entirely new models to analyze every aspect of biomedical sciences during the last decade. In the study of cancer, the CRISPR/CRISPR-associated protein (Cas) system opens new avenues into issues that were once unknown in our knowledge of the noncoding genome, tumor heterogeneity, and precision medicines. CRISPR/Cas-based gene-editing technology now allows for the precise and permanent targeting of mutations and provides an opportunity to target small non-coding RNAs such as microRNAs (miRNAs). However, the development of effective and safe cancer gene editing therapy is highly dependent on proper design to be innocuous to normal cells and prevent introducing other abnormalities. This study aims to highlight the cutting-edge approaches in cancer-gene editing therapy based on the CRISPR/Cas technology to target miRNAs in cancer therapy. Furthermore, we highlight the potential challenges in CRISPR/Cas-mediated miRNA gene editing and offer advanced strategies to overcome them.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: